
While insulin remains the mainstay of T1D treatment, insulin resistance increases the risk of complications. This review explores adjunctive therapies—metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and thiazolidinediones—for their metabolic, cardiovascular, and renal benefits. A pragmatic approach is proposed to optimize glycaemic control in high-risk individuals, highlighting knowledge gaps and future research needs.
Like
Save
Share